We may earn commissions if you use the recommended services on this site.  

MoonLake Immunotherapeutics Unveils Groundbreaking Phase 2 Findings for Nanobody® Sonelokimab in Active Psoriatic Arthritis

Latest Business News

MoonLake Immunotherapeutics Reports Positive Phase 2 Results for Nanobody® Sonelokimab in Psoriatic Arthritis

MoonLake Immunotherapeutics, a biotechnology company focused on innovative therapies for inflammatory diseases, has announced positive top-line results from its Phase 2 ARGO trial evaluating the Nanobody® sonelokimab in patients with active psoriatic arthritis (PsA).

Groundbreaking Trial Results

The ARGO trial, a placebo-controlled randomized trial, demonstrated positive outcomes for sonelokimab in treating PsA. The trial met its primary endpoint, with a significant proportion of patients treated with sonelokimab achieving an American College of Rheumatology (ACR) 50 response compared to the placebo group at week 12. Key secondary endpoints, including Psoriasis Area and Severity Index (PASI) 90, also showed positive results.

Potential Best-in-Class Profile

Sonelokimab demonstrated a potential best-in-class profile, outperforming the active reference arm, adalimumab, on primary and secondary endpoints. The trial results support sonelokimab as a leading therapy option for PsA, with high clinical responses observed across joint and skin endpoints.
Promising Safety Profile
The ARGO trial demonstrated a low patient discontinuation rate and a safety profile consistent with previous studies of sonelokimab. No new safety signals were observed, and the drug showed a favorable safety profile.
Future Development
The positive results from the ARGO trial mark a significant milestone for MoonLake Immunotherapeutics. The company plans to advance its Phase 3 program for PsA based on these encouraging findings. The potential of sonelokimab to revolutionize treatment options for PsA is highly anticipated. In conclusion, the Phase 2 results for sonelokimab in PsA demonstrate its efficacy, safety, and potential as an innovative treatment option for patients with active psoriatic arthritis. MoonLake Immunotherapeutics continues to pave the way for groundbreaking therapies in inflammatory diseases. MoonLake Immunotherapeutics' recent announcement of positive Phase 2 results for Nanobody® sonelokimab in psoriatic arthritis (PsA) patients could mark a significant turning point for new businesses in the biotechnology industry. The ARGO trial's groundbreaking results not only demonstrate the efficacy of sonelokimab in treating PsA, but also its potential to outperform existing therapies. This could create a ripple effect in the industry, encouraging other businesses to explore and invest in innovative therapies for inflammatory diseases. The trial's promising safety profile further solidifies sonelokimab's potential as a leading therapy option. This could significantly impact the competitive landscape, pushing new businesses to prioritize safety alongside efficacy in their research and development efforts. MoonLake's plan to advance its Phase 3 program based on these encouraging findings could potentially revolutionize treatment options for PsA. This is a clear indication of the immense potential of innovative therapies in transforming patient care. In conclusion, MoonLake Immunotherapeutics' positive Phase 2 results for sonelokimab in PsA could significantly influence new businesses in the biotechnology industry. The results not only demonstrate the potential of innovative therapies in treating inflammatory diseases, but also underscore the importance of safety and efficacy in drug development.
Story First Published at: https://financialpost.com/globe-newswire/moonlake-immunotherapeutics-announces-landmark-phase-2-results-for-nanobody-sonelokimab-in-active-psoriatic-arthritis
Brought to you by BusinessFormation.io
Know Your State's Registered Agent Requirements: What is a Registered Agent
Learn How To Create An LLC: What Is An LLC and How To Start an LLC Online
Business Formation Services: View Top 3 Online LLC Filing Companies

LLC Filing & Registered Agent Services

Compare Online LLC Filing Services Today

We work with the market leaders in business formation and registered agent services.

Getting started is simple and inexpensive. Form your business today & secure your brand name before someone beats you to it! Click below to view the Top 3 Best LLC and registered agent service providers.
View Top 3 Providers Now

Filing An LLC Can Be Complicated

Streamline Your LLC Filing Online for $39

Northwest Registered Agent is the best-rated service for first time filers.

Get professional LLC formation & registered agent services for only $39 + state filing fee. This offers includes your full LLC setup, plus a private business address, lifetime support, and more.

Trusted by Millions. Save 82% Today.